The importance of the crosstalk between P2X7 and CD39 in the TME is further confirmed by the finding that CD39-targeting antibodies require a functional P2X7 receptor in immune cells to work appropriately as antitumoral agents in primary and metastatic murine tumor models [82,83]. The gene discussed is P2RX7; the disease is neoplasm.